1. Home
  2. BOLD vs GROW Comparison

BOLD vs GROW Comparison

Compare BOLD & GROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BOLD
  • GROW
  • Stock Information
  • Founded
  • BOLD 2018
  • GROW 1968
  • Country
  • BOLD United States
  • GROW United States
  • Employees
  • BOLD N/A
  • GROW N/A
  • Industry
  • BOLD
  • GROW Investment Managers
  • Sector
  • BOLD
  • GROW Finance
  • Exchange
  • BOLD Nasdaq
  • GROW Nasdaq
  • Market Cap
  • BOLD 24.4M
  • GROW 31.8M
  • IPO Year
  • BOLD 2024
  • GROW N/A
  • Fundamental
  • Price
  • BOLD $1.21
  • GROW $2.46
  • Analyst Decision
  • BOLD Buy
  • GROW
  • Analyst Count
  • BOLD 3
  • GROW 0
  • Target Price
  • BOLD $4.00
  • GROW N/A
  • AVG Volume (30 Days)
  • BOLD 279.6K
  • GROW 41.8K
  • Earning Date
  • BOLD 08-11-2025
  • GROW 09-09-2025
  • Dividend Yield
  • BOLD N/A
  • GROW 3.66%
  • EPS Growth
  • BOLD N/A
  • GROW N/A
  • EPS
  • BOLD N/A
  • GROW 0.01
  • Revenue
  • BOLD N/A
  • GROW $8,932,000.00
  • Revenue This Year
  • BOLD N/A
  • GROW N/A
  • Revenue Next Year
  • BOLD N/A
  • GROW N/A
  • P/E Ratio
  • BOLD N/A
  • GROW $234.30
  • Revenue Growth
  • BOLD N/A
  • GROW N/A
  • 52 Week Low
  • BOLD $1.00
  • GROW $2.02
  • 52 Week High
  • BOLD $4.72
  • GROW $2.73
  • Technical
  • Relative Strength Index (RSI)
  • BOLD N/A
  • GROW 56.26
  • Support Level
  • BOLD N/A
  • GROW $2.35
  • Resistance Level
  • BOLD N/A
  • GROW $2.58
  • Average True Range (ATR)
  • BOLD 0.00
  • GROW 0.09
  • MACD
  • BOLD 0.00
  • GROW -0.01
  • Stochastic Oscillator
  • BOLD 0.00
  • GROW 36.36

About BOLD Boundless Bio Inc. Common Stock

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

About GROW U.S. Global Investors Inc.

US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.

Share on Social Networks: